Business Context and Reporting Period
This Form 10-Q covers PerkinElmer, Inc. (Note: The request metadata lists "REVVITY, INC.", but the filing text identifies the registrant as PerkinElmer, Inc.) for the quarterly period ended September 30, 2001, and the nine months ended September 30, 2001. The company operates in three strategic business units: Life Sciences, Optoelectronics, and Instruments. During this period, the company classified its Fluid Sciences and Security and Detection Systems businesses as discontinued operations pending sale.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2001 | Nine Months Ended Sep 30, 2001 |
|---|---|---|
| Sales (Continuing Ops) | $302.1 million | $968.8 million |
| Net Income (Total) | $31.2 million | $84.1 million |
| Net Income (Continuing Ops) | $21.6 million | $54.6 million |
| Diluted EPS (Total) | $0.30 | $0.81 |
| Operating Income (Continuing Ops) | $33.3 million | $101.4 million |
| Gross Margin % | 46% | 46% |
| Cash and Equivalents | $128.4 million | $128.4 million (End of Period) |
| Short-Term Debt | $223.6 million | $223.6 million (End of Period) |
| Long-Term Debt | $593.9 million | $593.9 million (End of Period) |
| Operating Cash Flow (Continuing) | N/A | $28.0 million |
Material Changes vs. Prior Period
- Revenue: Third-quarter sales declined 11% to $302.1 million compared to $340.1 million in the prior year. However, nine-month sales increased 1% to $968.8 million. Organic revenue declined 7% in the quarter due to a 16% drop in Optoelectronics and an 8% drop in Instruments, partially offset by 12% growth in Life Sciences.
- Profitability: Operating income from continuing operations surged to $33.3 million in the quarter from $9.0 million in the prior year. This improvement was driven by a 46% gross margin (up from 44%) and the absence of a $24.3 million in-process research and development charge recorded in the prior year's third quarter.
- Discontinued Operations: The company reported $9.6 million in income from discontinued operations for the quarter, primarily from the Fluid Sciences and Security and Detection Systems units.
- Restructuring: The company recorded restructuring charges of $12.6 million related to the 2000 plan and $10.8 million related to acquisition integrations (AI and NEN) during the nine-month period.
Guidance, Outlook, and Risks
- Acquisitions: The company announced a proposed acquisition of Packard BioScience Company, expected to close in the fourth quarter of 2001. The transaction involves issuing stock and assuming options.
- Divestitures: Plans to sell the Fluid Sciences and Security and Detection Systems businesses were approved. These are now reported as discontinued operations.
- Market Risks: The company faces exposure to foreign exchange rate fluctuations (hedged via forward contracts) and interest rate changes. Management utilizes a Value-at-Risk model to monitor these exposures.
- Accounting Changes: The company is assessing the impact of new FASB standards (SFAS No. 141, 142, 143, and 144) regarding business combinations, goodwill, and asset retirement obligations, which will affect future reporting.
- Outlook: Management notes that results for the nine months ended September 30, 2001, are not necessarily indicative of full-year results. Organic growth in Life Sciences is offset by declines in Optoelectronics due to semiconductor and photography market deterioration.
Investor Verification Checklist
- Discontinued Operations: Verify the timeline and expected proceeds for the sale of the Fluid Sciences and Security and Detection Systems units.
- Acquisition Status: Confirm the regulatory approval status and closing date for the Packard BioScience acquisition.
- Debt Structure: Review the terms of the $478.9 million convertible debentures maturing in 2020 and the $300 million revolving credit facility expiring in March 2002.
- Organic Growth: Analyze the sustainability of the 12% organic growth in Life Sciences versus the 16% decline in Optoelectronics.
- Restructuring Costs: Monitor the remaining accrued restructuring costs ($24.0 million total) and expected cash outlays in fiscal 2001 and 2002.